Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's international revenue growth is a positive indicator, and the transition to branded products with strong retention is promising. However, the negative impact on gross margins due to restructuring costs and the unclear guidance on future margins and EBITDA dampens the outlook. Additionally, while AI and new category investments show potential, they also introduce uncertainty. Given the market cap of $4.3 billion, the stock is likely to experience a neutral movement, as the positive and negative factors balance each other out.
Key Financial Performance
Revenue Revenue grew 4% year-over-year to $608 million. The growth was temporarily pressured by revenue recognition dynamics from shorter shipping cadences and a tougher comparable period due to record-level additions of weight loss subscribers in the first quarter of last year.
Subscribers Subscribers grew 9% year-over-year to nearly 2.6 million. This growth reflects the company's ability to attract and retain customers through its expanding offerings and platform capabilities.
Adjusted EBITDA Adjusted EBITDA was $44 million, representing a 7% adjusted EBITDA margin. This was impacted by restructuring costs and investments in technology and operations.
Gross Margins Gross margins were 65% on a GAAP basis and 70% when adjusted for restructuring costs. The restructuring costs, primarily related to the write-downs of compounded GLP-1 supply chain, negatively impacted gross margins by roughly 5 points.
International Revenue International revenue increased nearly tenfold from the first quarter to $78 million, driven by acquisitions of ZAVA and Livewell.
Restructuring Costs Approximately $33 million of restructuring costs were incurred, primarily consisting of write-downs related to the compounded GLP-1 supply chain that now faces risk of obsolescence.
Cash Flow Generated $89 million of cash flow from operations and $53 million of free cash flow. This reflects the company's ability to maintain strong cash flow despite strategic pivots and investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Specialties: Momentum in newer specialties like testosterone, menopause, and labs. Expanded selection of branded GLP-1 solutions driving growth in weight loss business.
Weight Loss Strategy: Shifted to a globally unified approach, introducing direct access to Novo Nordisk's GLP-1 products. Fulfilled over 125,000 shipments for Wegovy products within 6 weeks.
Peptide Therapies: Invested in a U.S.-based peptide facility to ensure high-quality treatments. Focused on physician insights and oversight for future launches.
Global Scale: Planned acquisition of Eucalyptus to expand leadership in consumer health across Australia, the U.K., Germany, Japan, and Canada.
International Growth: Revenue from international operations increased nearly tenfold to $78 million in Q1.
Technology Investments: Invested in AI and data infrastructure, including a 40-member AI team. Launched AI tools like Labs AI and AI weight loss companion to enhance customer experience.
Vertical Integration: Invested in facilities and talent to expand capabilities and operational efficiency, including at-home blood collection technology.
Marketing Efficiency: Improved marketing efficiency, reducing marketing as a percentage of revenue by 3 points year-over-year to 36% in Q1.
Weight Loss Business Pivot: Discontinued advertising of compounding products to prioritize branded offerings, expanding the addressable market significantly.
AI and Data Strategy: Embedded intelligence across the care journey, creating a closed-loop proprietary data flywheel for competitive advantage.
2030 Financial Targets: Aiming for $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges potential risks related to regulatory changes, particularly in emerging categories like peptides. The FDA's evolving stance on safety and allowable practices in this area could impact the company's ability to launch new products.
Supply Chain Risks: The strategic pivot in the weight loss specialty led to a $33 million restructuring cost, including write-downs of compounded GLP-1 supply chain assets, which now face obsolescence risks. This highlights vulnerabilities in supply chain investments.
Financial Volatility: The company anticipates volatility in GAAP financial results due to strategic pivots and investments in new markets and technologies. This could impact short-term profitability and financial stability.
International Expansion Risks: The planned acquisition of Eucalyptus and expansion into international markets like Canada, the U.K., and Australia involve significant investments and potential challenges in scaling operations and adapting to local regulatory environments.
Technology and AI Risks: Heavy investments in AI and technology infrastructure carry risks related to execution, cost overruns, and the ability to achieve the intended efficiencies and improvements in customer experience.
Market Competition: The company faces competitive pressures in the weight loss and health platform markets, particularly as it shifts focus to branded products like Wegovy. Competitors may challenge its ability to maintain market share and customer loyalty.
Customer Retention Risks: While the company is investing in technology and personalized care to improve customer retention, there is a risk that these efforts may not yield the desired long-term engagement and loyalty.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects revenue for the second quarter of 2026 to be between $680 million and $700 million, representing a year-over-year increase of 25% to 28%. For the full year, revenue is projected to be between $2.8 billion and $3 billion, reflecting a year-over-year increase of 19% to 28%.
Adjusted EBITDA: Adjusted EBITDA for the second quarter of 2026 is expected to range between $35 million and $55 million, with an adjusted EBITDA margin of 7% at the midpoint. For the full year, adjusted EBITDA is projected to be between $275 million and $350 million, implying an adjusted EBITDA margin of 11% at the midpoint.
Weight Loss Specialty: The company anticipates adding over 100,000 new subscribers per month within the weight loss specialty, driven by the introduction of branded products like Wegovy. This is expected to expand the addressable market significantly.
International Expansion: The planned acquisition of Eucalyptus is expected to close in the second half of 2026, extending the company's presence in Australia, the U.K., Germany, Japan, and Canada. Heavy investments are planned in international markets to establish category leadership.
Technology Investments: Continued investments in technology, including AI and at-home blood collection, are expected to enhance customer engagement and operational efficiency. These investments are anticipated to be financially accretive in the mid- to long-term.
Long-Term Financial Targets: The company reaffirms its 2030 financial targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company has $225 million remaining on its share repurchase program. This program allows the company to repurchase shares when it believes the intrinsic value of its stock meaningfully disconnects from the market value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the long-term vision for the recently launched Labs AI health care agent?
A:The long-term vision involves creating multiple AI agents to support each stage of the customer's journey across specialties. These agents will make the intake process more dynamic, assist with clinical decisions, and provide ongoing care and support. The goal is to integrate AI throughout the entire experience, enabling global access to Hims & Hers services with high-quality care.
Q:What is the company's long-term peptide strategy beyond GLP-1s?
A:The strategy includes leveraging their 503A compounding footprint for personalized dosing and formulations, utilizing their peptide manufacturing facility for a fully verticalized U.S. supply chain, and ensuring clinical oversight and protocols. They aim to lead the category safely and appropriately as the regulatory path becomes clearer.
Q:What is the contribution dollar profile for a branded customer versus a legacy compounded customer?
A:On a dollar basis, the two are roughly comparable. The strategic pivot to branded products has increased demand and traffic, benefiting the weight loss specialty and other specialties through cross-selling opportunities.
Q:What portion of compounded GLP-1 subscribers have transitioned to branded products, and what does retention look like?
A:Almost all new business is now on the branded side, with many transitioning over. This transition has resulted in over 100,000 new customers for Wegovy, with strong retention and increased customer acquisition.
Q:How far along is the company in terms of readiness to go to market if the FDA reclassifies peptides in July?
A:The company is actively preparing for all necessary elements, including data transparency, validated supply chains, and clinical protocols. They aim to be best in market rather than first, ensuring safety and quality before launching.
Q:What are the expected gross margin trends and EBITDA margins for the back half of the year?
A:Gross margins are expected to degrade by a couple of points due to strategic pivots, but the company remains focused on driving strong absolute EBITDA dollars and free cash flow. Incremental margins are expected to improve due to cohort stacking, G&A leverage, and marketing efficiency.
Q:What is the dynamic of revenue guidance increasing while EBITDA guidance decreases?
A:The company is prioritizing investments to establish leadership positions in the U.S. and globally. This includes scaling new categories like labs, testosterone, and menopause, which may initially impact margins but are expected to drive long-term growth and economies of scale.
Q:How is AI expected to change the user experience over time?
A:AI will enable multi-agent models to optimize and personalize customer journeys, improve care quality, and enhance engagement. This includes faster responses, personalized recommendations, and ongoing support, leading to better retention and deeper customer relationships.
Q:What is the company's approach to wearables?
A:The company is exploring both building their own devices and partnering with existing players. They aim to integrate wearables seamlessly into the Hims & Hers experience, leveraging data to improve care and engagement.
Q:What is the brand manufacturer value proposition, and how does it extend beyond GLP-1s?
A:The value proposition includes providing distribution for innovative categories like pharma, biotech, and devices. Hims & Hers offers the largest geographic footprint and deep consumer relationships, helping partners scale growth and deliver the right care to the right customers.
Q:Are the new categories like weight-loss, labs, testosterone, and menopause primarily U.S.-based drivers?
A:Yes, these categories are primarily U.S.-based drivers currently. The company plans to refine and optimize these categories domestically before expanding them internationally.
Q:Review of Unclear Management Responses
A:Management avoided directly quantifying the impact of the weight loss strategic pivot on the full-year revenue and EBITDA guide. Additionally, they did not provide a clear long-term gross margin range despite being asked about it.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Novo
access
advantage
approach
area progress
blood
category
condition
customer experience
efficacy
end
experience life
factor
future
health care
health innovator
infrastructure
insight
investment
journey
million
model
network
offering
outcome
partner
people
platform
point
provider
quality
relationship
release
scale
support
testosterone
treatment
way
weight loss
HIMS Transcript
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Unknown5-12
The company's international revenue growth is a positive indicator, and the transition to branded products with strong retention is promising. However, the negative impact on gross margins due to restructuring costs and the unclear guidance on future margins and EBITDA dampens the outlook. Additionally, while AI and new category investments show potential, they also introduce uncertainty. Given the market cap of $4.3 billion, the stock is likely to experience a neutral movement, as the positive and negative factors balance each other out.
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Neutral3-2
Hims & Hers Health, Inc. (HIMS) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call reveals strong financial performance with a 50% revenue increase and improved margins. The company turned a net income from a loss, indicating operational improvements. Although risks are acknowledged, the positive financial metrics and strategic initiatives outweigh them. The market cap suggests moderate sensitivity to news, leading to a positive stock price prediction of 2% to 8%.
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call summary reveals strong financial performance with optimistic guidance, including a projected revenue growth of 42% to 47% for Q3 2025 and a robust full-year growth outlook. The company is expanding into new markets and specialties, indicating future growth potential. Despite some uncertainties regarding margin contraction, the overall sentiment remains positive due to strategic investments and international expansion plans. The market cap suggests a moderate reaction, leading to a prediction of a 2% to 8% stock price increase.
HIMS Slides
HIMS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
